MARKET

PODD

PODD

Insulet
NASDAQ

Real-time Quotes | Nasdaq Last Sale

289.20
-1.40
-0.48%
After Hours: 289.20 0 0.00% 16:07 09/24 EDT
OPEN
289.11
PREV CLOSE
290.60
HIGH
291.69
LOW
287.00
VOLUME
177.53K
TURNOVER
--
52 WEEK HIGH
309.99
52 WEEK LOW
213.51
MARKET CAP
19.92B
P/E (TTM)
-628.0130
1D
5D
1M
3M
1Y
5Y
Here's Why You Should Retain Insulet (PODD) Stock for Now
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
Zacks · 19h ago
Andreas Halvorsen Assembles Position in PROCEPT BioRobotics
GuruFocus News · 2d ago
Brown Capital Management Mid Company Fund Buys Insulet Corp, Coupa Software Inc, Veeva Systems Inc
GuruFocus News · 6d ago
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
Zacks.com · 09/07 14:15
Insulet Corp (PODD) EVP and CCO Bret Christensen Sold $882,390 of Shares
GuruFocus News · 08/30 18:01
Renalytix Appoints Daniel J. Levangie to its Board of Directors
Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Company's board of directors. Mr. Levangie is also appointed as a member of the Company's remuneration committee.
GlobeNewswire · 08/30 11:00
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass., August 26, 2021--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming virtual investor conferen...
Business Wire · 08/26 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PODD. Analyze the recent business situations of Insulet through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PODD stock price target is 290.41 with a high estimate of 325.00 and a low estimate of 250.00.
EPS
Institutional Holdings
Institutions: 605
Institutional Holdings: 77.59M
% Owned: 112.66%
Shares Outstanding: 68.87M
TypeInstitutionsShares
Increased
151
4.24M
New
66
1.70M
Decreased
162
3.41M
Sold Out
54
2.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Scannell
President/Chief Executive Officer/Director
Shacey Petrovic
Chief Financial Officer/Executive Vice President/Treasurer
Wayde McMillan
Chief Operating Officer/Executive Vice President
Charles Alpuche
Chief Human Resource Officer/Senior Vice President
Dan Manea
Executive Vice President
Bret Christensen
Senior Vice President/General Counsel/Secretary
John Kapples
Senior Vice President
Eric Benjamin
Senior Vice President
Michael Spears
Independent Director
Sally Crawford
Independent Director
Wayne Frederick
Independent Director
James Hollingshead
Independent Director
Jessica Hopfield
Independent Director
David Lemoine
Independent Director
Michael Minogue
Independent Director
Corinne Nevinny
No Data
  • All
  • Financials
  • Insiders
More
About PODD
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.

Webull offers kinds of Insulet Corporation stock information, including NASDAQ:PODD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PODD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PODD stock methods without spending real money on the virtual paper trading platform.